Company intelligence / Profile preview

Synaffix

Ownership: Public · LONN
Development stage: Phase 2

Overview

The Synaffix ADC platform has enabled more than five clinical-stage programs with partners, demonstrating improved efficacy and tolerability in next-generation ADCs. Over twenty distinct targeted cancer therapeutics are being developed using the technology across multiple collaborations. No direct clinical trial results are published by Synaffix itself, as it operates a licensing model rather than developing its own drug pipeline[4][5].

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)Bispecific antibodiesPeptide and protein-based payloads
Industry: Drug Discovery Services

Drug pipeline

2 assets

IBI343

Phase 1

Indications: Cancer

1 more asset in the full pipeline.

Partnerships

Amgen[6]Mersana Therapeutics[4]Genmab[4]Macrogenics[4]Kyowa Kirin[4]Emergence Therapeutics/Eli Lilly & Co.[5]Janssen/J&J [5]Shanghai Miracogen [5]Innovent Biologics [5]ProfoundBio [5]– Hummingbird Bioscience [5]– Amgen [6], Chong Kun Dang Pharm, ADC Therapeutics

Beyond the preview

Go deeper on Synaffix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaffix.